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Background: Multi-element interventions for first-episode psychosis (FEP) are promising, but have mostly been
conducted in non-epidemiologically representative samples, thereby raising the risk of underestimating the
complexities involved in treating FEP in ‘real-world’ services.
Methods/Design: The Psychosis early Intervention and Assessment of Needs and Outcome (PIANO) trial is part of a
larger research program (Genetics, Endophenotypes and Treatment: Understanding early Psychosis - GET UP) which
aims to compare, at 9 months, the effectiveness of a multi-component psychosocial intervention versus treatment
as usual (TAU) in a large epidemiologically based cohort of patients with FEP and their family members recruited
from all public community mental health centers (CMHCs) located in two entire regions of Italy (Veneto and Emilia
Romagna), and in the cities of Florence, Milan and Bolzano. The GET UP PIANO trial has a pragmatic cluster
randomized controlled design. The randomized units (clusters) are the CMHCs, and the units of observation are the
centers’ patients and their family members. Patients in the experimental group will receive TAU plus: 1) cognitive
behavioral therapy sessions, 2) psycho-educational sessions for family members, and 3) case management. Patient
enrolment will take place over a 1-year period. Several psychopathological, psychological, functioning, and service
use variables will be assessed at baseline and follow-up. The primary outcomes are: 1) change from baseline to
follow-up in positive and negative symptoms’ severity and subjective appraisal; 2) relapse occurrences between
baseline and follow-up, that is, episodes resulting in admission and/or any case-note records of re-emergence of
positive psychotic symptoms. The expected number of recruited patients is about 400, and that of relatives about
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http://www.trialsjournal.com/content/13/1/73Owing to the implementation of the intervention at the CMHC level, the blinding of patients, clinicians, and raters
is not possible, but every effort will be made to preserve the independency of the raters. We expect that this study
will generate evidence on the best treatments for FEP, and will identify barriers that may hinder its feasibility in
‘real-world’ clinical settings, patient/family conditions that may render this intervention ineffective or inappropriate,
and clinical, psychological, environmental, and service organization predictors of treatment effectiveness,
compliance, and service satisfaction.
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It has been suggested that most clinical and psychosocial
deterioration in psychosis occurs within the first 5 years
of illness onset, and that this timeframe is a crucial
period for initiating treatment [1]. Recent research
efforts have therefore focused on early detection and
intervention for psychosis, showing that the beneficial
effects of antipsychotic medication on first-episode
psychosis (FEP) are tempered by the fact that, despite
initial symptom reduction, functional recovery is typic-
ally poor even when optimal pharmacological treatment
is provided [2]. Family members are also affected by the
emotional burden of being caregivers, and often show
signs of psychological distress themselves [3]. It is clear
from the literature that pharmacotherapy alone is not
sufficient to prevent relapses or assure functional recov-
ery from acute psychosis [4].
Over the past few years, there has been a growing
interest in psychosocial intervention as a means of facili-
tating recovery and reducing long-term disability asso-
ciated with psychosis [5]. Literature on psychosocial
interventions in FEP can be viewed in terms of two
broad categories [6]: 1) studies evaluating specific (that
is, single-element) psychosocial interventions (for ex-
ample, individual cognitive behavioral therapy), and 2)
studies evaluating comprehensive (that is, multi-elem-
ent) interventions, which may include: early detection
strategies; individual, group, and/or family therapy; and
case management (in addition to pharmacological treat-
ment). These interventions appear promising [7] and
have been found to be associated with symptom reduc-
tion/remission, improved quality of life, increased social
and cognitive functioning, low inpatient admission rates,
improved insight, high degree of satisfaction with treat-
ment, less time spent in hospital, decreased substance
abuse, and fewer self-harm episodes.
However, most multi-element research programs have
been conducted in non-epidemiologically representative
samples in experimental settings, thereby raising the risk of
underestimating the complexities involved in treating FEP
in ‘real-world’ services [8]. Moreover, these interventions
have rarely been tested for their efficacy against a controlgroup, but more typically against historical or prospective
comparison groups, and usually only single-group studies
have been carried out, which track the progress of a single
group over a given period.
With respect to clinical practice, some countries have
implemented specific early psychosis interventions over
the past 10 years, but even these have not yet become
routine [9]. Few studies have identified barriers that may
hinder the feasibility of these interventions or the patient
or family conditions that may render this type of treat-
ment ineffective or inappropriate. Hence, efforts to im-
plement multi-element interventions targeted to FEP in
routine services should be accompanied by rigorous sci-
entific method, with the aim of better understanding the
actual effectiveness of this approach [10,11].
Methods/Design
Aims
The Psychosis early Intervention and Assessment of Needs
and Outcome (PIANO) trial is part of the larger research
program termed Genetics Endophenotypes and Treatment:
Understanding early Psychosis (GET UP; national coord-
inator: Professor Mirella Ruggeri, Verona), funded by the
Italian Ministry of Health as part of a National Health
Care Research Program (Ricerca Sanitaria Finalizzata)
coordinated by the Academic Hospital of Verona (Azienda
Ospedaliera Universitaria Integrata Verona).
GET UP consists of four partner projects : PIANO,
TRaining and Understanding of service Models for Psych-
osis Early Treatment (TRUMPET), Genetic data Utilization
and Implementation of Targeted drug Administration in
the clinical Routine (GUITAR) and COgnitive Neuroendo-
phenotypes for Treatment and RehAbilitation of psychoses:
Brain imaging, InflAmmation and StresS (CONTRABASS).
Each of these partner projects pertains to different areas of
research, but they are linked together.
The GET UP PIANO trial described here is the main
data collection axis for the overall GET UP Research Pro-
gram. The trial has three aims:
1) To compare, at 9 months, the effectiveness of a
multi-component psychosocial intervention with
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epidemiologically based cohort of patients with FEP
and their family members recruited from a 10
million-inhabitant catchment area.
2) To identify the barriers that may hinder its feasibility
in real-world routine clinical settings and patient/
family conditions that may render this intervention
ineffective or inappropriate.
3) To identify clinical, psychological, environmental,
and service organization predictors of treatment
effectiveness, compliance, and service satisfaction in
FEP in the Italian community mental healthcare
framework.
Study participants are recruited from community men-
tal health centers (CMHCs) operating for the Italian Na-
tional Health Service and located in two entire regions
of Italy (Veneto and Emilia Romagna), and in the cities
of Florence, Milan and Bolzano. For administrative and
research purposes, the overall territory covered by the
GET UP has been divided into eight macro-areas,
named participating units (PUs): Western Veneto, East-
ern Veneto, Emilia, Romagna, Florence, Bolzano, Milan
Niguarda, and Milan San Paolo.
Design
The PIANO trial has a pragmatic cluster randomized con-
trolled design [12,13], which compares the effectiveness of
TAU plus a multi-element psychosocial treatment for
patients with FEP and their family members, versus TAU
alone, as provided by Italian community mental health ser-
vices. A cluster design was chosen based on feasibility con-
siderations, supported by the MRC Health Services and
Public Health Research Board [14], which indicated that
cluster randomization is the gold standard approach for
trials evaluating similar complex interventions implemen-
ted at the institutional level, with the aim of improving
health. The assignment units (clusters) are the CMHCs
located in the catchment area, and the units of observation
and analysis are the CMHC patients and their family mem-
bers. Each CMHC belongs to the Department of Mental
Health (DMH), which is responsible for all mental health
care (including outpatient, inpatient, and long-term resi-
dential care) for a specific catchment area. Each DMH can
include one or several CMHCs, depending on the size of
the DMH catchment area.
Inclusion and exclusion criteria
Inclusion criteria are based on the screening method
adopted in the WHO 10-country study [15], and include:
 Age 18–54 years.
 Residence in the catchment area of participating
CMHCs. Presence of 1) at least one of the following
symptoms: hallucinations, delusions, qualitative
speech disorder, qualitative psychomotor disorder,
bizarre or grossly inappropriate behavior; or 2) at
least two of the following symptoms: loss of interest,
initiative and drive, social withdrawal, episodic
severe excitement, purposeless destructiveness,
overwhelming fear, marked self-neglect, as measured
by the Screening Schedule for Psychosis [15].
 First lifetime contact with participating CMHCs,
prompted by the symptoms enumerated in the point
above.
Exclusion criteria are:
 Pre-existing anti-psychotic medication (> 3 months)
prescribed by any psychiatric or other medical
agencies for a mental disorder identical or similar to
the current one.
 Mental disorders due to a general medical condition.
 Moderate to severe mental retardation as
determined by clinical functional assessment.
 An ICD-10 diagnosis other than F20-F29, F30.2,
F31.2, F31.5, F31.6, F32.3, F33.3, F1x.4; F1x.5, F1x.7,
F1x.8, F1x.9, as confirmed after 9 months by using
the Schedule for Clinical Assessment in
Neuropsychiatry (SCAN) [16].Ethical issues
This study is being conducted in accordance with globally
accepted standards of good clinical practice, in agreement
with the Declaration of Helsinki, and in keeping with local
regulations.
GET UP PIANO investigators ensure that all profes-
sionals involved in the trial are adequately qualified and
informed about the protocol, the study interventions, and
their trial-related duties and functions. The coordinating
center maintains a list of all appropriately qualified persons
involved in the study.Ethics committee approval
Formal ethics approval for conducting the trial has been
sought and obtained by the Coordinating Center’s Ethics
Committee (Comitato Etico per la Sperimentazione,
Azienda Ospedaliera di Verona, http://www.ospedaliver-
ona.it/Istituzionale/Comitati-Etici/Sperimentazione), which
approved the study protocol, the information sheets (pa-
tient and family versions), and the informed consent sheets
(patient and familiar versions) on 6 May 2009 (Prot. N.
20406/CE, Date 14/05/2009), and by the ethics committee
of each participating unit.
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Experimental treatment
The experimental treatment package is provided by rou-
tine public CMHCs, which operate within the Italian
National Health Service and consists of TAU (see next
paragraph) plus evidence-based additional treatment.
Specifically, the additional treatment comprises three
main forms of intervention: 1) cognitive behavioral therapy
for psychosis (CBTp) for patients; 2) family intervention
for psychosis (FIp); and 3) case management (CM).
CBTp is based on the model developed by Kuipers
et al. [17], Garety et al. [18] and Fowler et al. [19], and
the model has already been evaluated in randomized
controlled trials [20]. It is expected that an optimal
number of 20–30 CBT sessions per patient will be deliv-
ered during a time frame of 9 months, with weekly ses-
sions held during the first 3 months and fortnightly
during the following 6 months. Family intervention is
based on the model proposed by Leff et al. [21] and fur-
ther developed by Kuipers et al. [22]. It consists of an
optimal number of 10–15 sessions over 9 months with
each individual family: 6 sessions in the first 3 months,
and at least 1 session/month during the following
6 months. For case management, every patient/family
has a dedicated case manager, who coordinates all
planned interventions.
Experimental interventions are expected to begin as
soon as the patient is stabilized (clinical stabilization is
defined as a condition allowing the patient to collaborate
in at least a brief clinical examination) and after he/she
has been assessed with the ‘core’ set of baseline measures
(see ‘Baseline assessment’ below). Before the start of the
trial, professionals using the experimental interventions
received specific training programs in CBTp (conducted
as part of the scientific aims of the GET UP PIANO
Project), FIp, and CM (conducted as part of the scien-
tific aims of the GET UP TRUMPET Project). At the
end of the training, an assessment of the competence
achieved was performed, and detailed intervention
manuals based on international standards were devel-
oped and given to the professionals as a standard to be
followed for the treatment. Professionals are supported
in their clinical work by a team of expert psychothera-
pists assigned to each CMHC. Moreover, experimental
interventions provided to all patients/relatives are
supervised by a team of external experts who hold one-
day meetings every 2 months and are regularly available
for consultation.
Fidelity will be measured at the end of the trial by an in-
dependent team by using audiotape recordings of therapy
sessions, and therapists ratings of their own session. The
Cognitive Therapy Scale-Revised (CTRS) [23] and the Cog-
nitive Therapy for Psychosis Adherence Scale (CTPAS) [24]
will be used, together with ad hoc checklists based on thespecific trial intervention manuals, in accordance with the
method described in Mc Hugo et al. [25].
Treatment as usual
TAU is also provided by routine public CMHCs operat-
ing within the Italian National Health Service, as above.
Standard care for patients with FEP typically consists of
personalized outpatient psychopharmacological treatment,
combined with non-specific supportive clinical manage-
ment at the CMHC level. Family interventions generally
consist of non-specific informal support/educational
sessions. Specialized individual psychotherapeutic inter-
ventions (including CBT) for patients and specialized
psychoeducational or cognitive-oriented family inter-
ventions are usually not provided because of the lack of
trained professionals [26,27].
Enrollment procedure for community mental health
centers
The GET UP PIANO trial catchment area covers 126
CMHCs (9,951,306 inhabitants), all of which were offi-
cially asked to participate in GET UP; 117 agreed to
participate, covering a catchment area of 9,304,093
inhabitants. In an effort to improve the efficiency of the
study design, CMHCs were stratified before randomization,
based on three variables: affiliation to the same DMH,
CMHC catchment area size, and type of area (urban/mixed
versus rural). Socioeconomic levels in the trial catchment
area were not considered as stratification variables as they
were found to be reasonably homogeneous. With the ex-
ception of staff members in five of the CMHCs (covering a
catchment area of 503,000 inhabitants) the mental health
staff of the remaining 112 CMHCs had received no previ-
ous training in the intervention. These first 5 centers were
therefore ‘forced’ into the intervention arm and used as the
expected ‘gold standard’ in the analysis, in order to measure
the competence of the remaining professionals. Thus, 112
CMHCs (8,801,093 inhabitants) were available for the
randomization procedure. Because of organizational needs,
32 small CMHCs were paired, based on their affiliation to
the same community psychiatric service, thus resulting in
16 randomization units. Hence, in total, 96 units entered
the randomization procedure.
Enrollment procedure for patients and family members
The CMHCs participating in the study are asked to refer
all potential cases of psychosis at their first contact with
the service over a period of 1 year. The Screening Sched-
ule for Psychosis [15] is administered to all patients as
soon as possible after first service contact, and must be
administered within 15 days. Inclusion criteria are based
on the screening methodology adopted in the WHO 10-
country study [15].
Table 1 Study schedule: instruments used at baseline and
follow-up assessments in the Genetics, Endophenotypes
and Treatment: Understanding Early Psychosis (GET UP)
Psychosis Early Intervention and Assessment of Needs
and Outcome (PIANO) trial
Enrolment
(12 months)
Baseline Follow-up
(9 months
from
baseline)
Patients
Review of inclusion criteria X
Informed consent signed X
Consent for involvement
of family members
X
Sociodemographic and
clinical data
X
Instruments
Core set: PANSS, HAM-D,
BRMRS, GAF, DAS
X X
TIB, Life events (CECA-Q, PBI),
neuropsychological
tests (WCST, AX-CPT, WAIS)
X
CDUS, PSYRATS, SAI-E,
CAN-EU, WHOQOL-Bref, LEE
X X
LCS, VSSS-EU X
SCAN X
Psychosocial/pharmacological
treatment/admissions
schedule
X
VITreT X
Reporting of pharmacological
side-effects and other
adverse events
X X
Family members
Informed consent signed X
IEQ-EU, GHQ X X
PSA X
VSSS-Relatives X
AX-CPT, AX-Continuous Performance Test; BRMRS, Bech-Rafaelsen Mania
Rating Scale; CAN-EU, Camberwell Assessment of Needs; CDUS, Clinical Drug
Use Scale; CECA-Q, Childhood Experience of Care and Abuse Questionnaire;
DAS, Disability Assessment Scale; GAF, Global Assessment of Functioning;
GHQ, General Health Questionnaire; HAM-D, Hamilton Rating Scale for
Depression; IEQ-EU, Involvement Evaluation Questionnaire; LCS, Life Chart
Schedule; LEE, Level of Expressed Emotion Scale; PANSS, Positive and Negative
Syndrome Scale; PBI, Parental Bonding Instrument; PSA, Premorbid Social
Adjustment; PSYRATS, Psychotic Symptom Rating Scale; SAI-E, Schedule of
Assessment of Insight; SCAN, Schedule for Clinical Assessment in
Neuropsychiatry; TIB, Test Intelligenza Breve (Italian version of the New Adult
Reading Test); VITreT, Verona Interview for Treatment Termination; VSSS-EU,
Verona Service Satisfaction Scale, patient version; VSSS-Relatives, Verona
Service Satisfaction Scale, relatives version; WAIS, Wechsler Adult Intelligence
Scale; WCST, Wisconsin Card Sorting Test; WHOQOL-Bref World Health
Organization Quality of Life.
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meeting all inclusion criteria are invited to undertake
standardized assessments as soon as possible once they
achieve clinical stabilization (see ‘Baseline assessment’
paragraph). Eligible patients are also asked for consent
to involve a key family member in the assessments. An
independent, trained researcher conducts the informed
consent interview, as approved by the ethics committee
of the Coordinating Center at the Academic Hospital of
Verona and the local ethics committees. All participants
are informed that it is possible to withdraw consent to
assessments at any time. If the patient or the family
member does not agree to be assessed, the independent
researcher briefly records the reasons for refusal, when-
ever possible. Once informed consent is obtained, inde-
pendent researchers complete the baseline quantitative
assessments for both the participant and the family
member. As a minimum, the ‘core’ set of baseline assess-
ments (see ‘Baseline assessment’) are completed before
the beginning of treatment (either TAU plus experimen-
tal therapy or TAU alone). If the patient is not accessible
for baseline assessment (consent given but appointments
missed, lack of time, etc.), the interventions begin if pos-
sible with the same time schedule, and the core baseline
measures are retrospectively reconstructed by consulting
the patient’s case record.
From 1 May 2011, a checking procedure using both
screening and baseline assessment phases is being
undertaken in the CMHCs participating in the study, in
order to guarantee the completeness and the accuracy of
the recruitment procedure and to identify any missed
cases. Generally, this procedure is called the ‘leakage
study’ and is considered a fundamental part of pragmatic
epidemiologically based trials. All electronic and paper
information systems in the CMHCs are carefully scruti-
nized for any cases aged 18–54 years, presenting to the
services for the first time during the index period, ICD-
10 diagnostic codes of psychosis (F20-F29, F30.2, F31.2,
F31.5, F31.6, F32.3, F33.3, F1x.4; F1x.5, F1x.7, F1x.8,
F1x.9). These data are compared with case records to
confirm eligibility. This procedure will be completed on
31 January 2012. All identified patients will therefore be
invited to participate in the informed consent interview,
and the ‘core’ baseline measures (see ‘Baseline assess-
ment’) will be retrospectively reconstructed by consult-
ing the patient’s case record.
Baseline assessment
After clinical stabilization, patients are assessed by inde-
pendent evaluators with a set of standardized instru-
ments (Table 1) to measure: premorbid IQ (Italian
version of the New Adult Reading Test; Test Intelligenza
Breve (TIB)) [28], substance abuse (Clinical Drug Use
Scale; CDUS) [29], symptoms (Positive and NegativeSyndrome Scale; PANSS) [30], (Hamilton Rating Scale
for Depression; HAMD) [31], (Bech-Rafaelsen Mania
Rating Scale; BRMRS) [32]], global functioning (Global
Assessment of Functioning; GAF) [33], subjective
Eligible CMHCs (n=126)
Population=9.951.306
Accepted to participate (n=117)
Population=9.304.093
Refused to participate (n=9)
Population=688.000
CMHCs allocated to intervention arm (n=48)
Population=4.573.983
CMHCs allocated to control arm (n=48)
Population=4.227.110
Eligible patients (n=) Eligible patients (n=)
Assessed at baseline (n=)
Not assessed at baseline; 
give reasons (n=)
Received intervention (n=)
Did not receive intervention; give reasons (n=)
Discontinued intervention; give reasons (n=)
*32 small CMHCs were paired on the basis of their affiliation to the same community psychiatric service
Received prior training for 
intervention (n=5)
Population=503.000
Randomized CMHCs (n=96)*
Population=8.801.093
Refused to begin the study (n=1)
Population=101.000
Assessed at follow-up (n=)
Lost to follow-up; give reasons (n=)
Assessed at baseline (n=)
Not assessed at baseline; 
give reasons (n=)
Assessed at follow-up (n=)
Lost to follow-up; give reasons (n=)
Analyzed (n=)
Excluded from analysis; give reasons(n=)
Analyzed (n=)
Excluded from analysis; give reasons (n=)
Figure 1 Flow diagram of Community Mental Health Centers (CMHCs) and patients in the Genetics, Endophenotypes and Treatment:
Understanding early Psychosis (GET UP) Psychosis early Intervention and Assessment of Needs and Outcome (PIANO) trial.
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ing Scale; PSYRATS) [34], social disability (Disability As-
sessment Scale; DAS) [35], insight (Schedule of
Assessment of Insight; SAI-E) [36], needs for care (Cam-
berwell Assessment of Needs; CAN-EU) [37], quality of
life (World Health Organization Quality of Life; WHO-
QOL-Bref ) [38], life events (first 14 years of life, 1 year
before the onset of psychosis and period after onset; ad
hoc schedule for life events [39]; Childhood Experience
of Care and Abuse Questionnaire (CECA-Q) [40]), par-
ental bonding (Parental Bonding Instrument; PBI) [41],
and expressed emotions (Level of Expressed Emotion
Scale; LEE) [42]. The ‘core’ set of baseline assessments
includes PANSS, HAM-D, BRMRS, GAF, and DAS.
Patients are also assessed by a set of tests evaluating
neuropsychological performance (such as Wisconsin
Card Sorting Test (WCST), AX-Continuous Perform-
ance Test (AX-CPT), and Wechsler Adult Intelligence
Scale (WAIS)).
Participating patients are asked for consent to involve
their family members in the trial. If this is given, family
members are also asked to provide written informed
consent, and are assessed about their burden of care (In-
volvement Evaluation Questionnaire; IEQ-EU) [43] and
emotional distress (General Health Questionnaire;
GHQ) [44]. They are also interviewed about the patient’s
premorbid adjustment (Premorbid Social Adjustment
scale; PSA) [45].
Before starting the assessments, the independent eva-
luators receive formal training in the use and adminis-
tration of the instruments, with measurement of their
skills and knowledge, and assessment of inter-rater
reliability.
Follow-up assessment
After a 9-month period from baseline assessment,
patients are reassessed to measure: substance abuse
(CDUS) [29], symptoms (PANSS [30], HAMD [31],
BRMRS [32]), global functioning (GAF) [33], subjective
appraisal of positive symptoms (PSYRATS) [34], social
disability (DAS) [35], insight (SAI-E) [36], need for care
(CAN-EU) [37] and quality of life (WHOQOL-Bref ) [38]
(Table 1). Patients are also evaluated in terms of
pharmacological side-effects and other adverse events,
pattern of clinical course (Life Chart Schedule; LCS) [46]
and service satisfaction (Verona Service Satisfaction
Scale, patient version; VSSS-EU) [47].
Family members are reassessed with respect to burden
of care (IEQ-EU) [43] and emotional distress (GHQ)
[44], and are also assessed for service satisfaction (VSSS,
relatives version; VSSS-Relatives) [47].
The formal best-estimate research diagnosis is assessed
at the 9-month follow-up using the item group checklist
of the SCAN [16]. All relevant baseline and follow-upinformation is obtained and reviewed by two independ-
ent raters to formulate the ICD-10 diagnosis. In cases
where a consensus is not reached, the opinion of a third
rater is solicited to clarify diagnostic problems.
Psychosocial and pharmacological treatment, together
with number and days of admission provided in the 9-
month follow-up period, are recorded in a detailed ad
hoc schedule.
All patients who have terminated contact with the ser-
vice before the 9-month follow-up are traced and asked
to undergo a semi-structured interview on the character-
istics of treatment termination (Verona Interview for
Treatment Termination, VITreT). This consists of 10
questions assessing: if the decision to interrupt service
contacts was shared or not with the key clinician; the
reason for interruption; which type of assistance was
eventually received thereafter in other settings, including
admission to hospital; and satisfaction with the care pro-
vided in these settings [48].
Randomization procedure
In total, 96 units entered the randomization procedure,
with equal numbers being allocated to each arm. These
units were randomly assigned to one of the two trial
arms with a 1:1 allocation rate. The trial statistician
(blind to CMHC identity) prepared the sequence of
treatments (experimental treatment versus TAU) ran-
domly permuted into blocks of two. The randomization
schedule was generated using Stata software (version
11.0; Stata Corp, Corp., College Station, TX, USA), using
the ‘ralloc’ command for random allocation of treat-
ments balanced in blocks. Subsequently, arm allocation
was disclosed to each CMCH, and the allocation se-
quence was not altered. One CMHC refused to begin
the study immediately after the randomization proced-
ure (Figure 1).
Eligible patients were assigned to treatment (experi-
mental intervention versus TAU) in accordance with the
allocation of CMHC pertaining to the catchment area of
residence.
Primary outcomes
The primary outcomes are:
 Changes from baseline to the 9-month follow-up
assessment in positive and negative symptom
severity and subjective appraisal, as measured by the
positive and negative subscales of the PANSS and by
the PSYRATS.
 Relapse occurrences during the period between
baseline and the 9-month follow-up assessment,
where relapse is defined as an episode that has
resulted in an admission to a psychiatric inpatient
unit (number and days of hospitalization) and/or
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period of full/partial remission of positive psychotic
symptoms of at least moderate degree requiring a
significant change in the clinical management (for
example, increased visiting or medication levels)
[49]. Consensus ratings will be made by paired
members of the research team (blind to the
randomization arm) using a priori operational
definitions.
In this pragmatic trial, two primary outcome measures
were defined in order to detect more finely-tuned clin-
ical changes also in those patients (nearly 60%) [50] who
are not expected to relapse over the study period, and in
those who have a continuous course of illness.
In addition to relapse occurrences, the number of
months in full or partial remission will be calculated in a
randomly selected subsample of 30% of the participating
subjects. This will be obtained by means of a published
method for rating remission in psychosis that has been
used in previous randomized controlled trials [18,49,50].
Consensus ratings will be made by paired members of
the research team using manualized a priori operational
definitions, a method with good validity and moderate
to good reliability [18,49]. Ratings are based on the level
of positive psychotic symptoms, and the technique will
be applied to detailed extracts of the clinical case notes.
These will consist of monthly reports over 9 months on
mental state and service interventions, from which all
information identifying the location of the clinical ser-
vice and the nature of treatment will have been removed.
Actual group allocation will remain concealed until all
ratings are complete. Data on all hospital admissions will
be retrieved from the hospital discharge records admin-
istrative database.
Secondary outcome measures
The secondary outcomes will be:
 change from baseline to 9 month follow-up in
patient functioning, assessed using the GAF and the
WHO-DAS;
 change from baseline to 9 month follow-up patient
emotional wellbeing, measured by using the anxiety
and depression items of the PANSS and the HAM-
D and selected items of the WHOQOL-Bref;
 service disengagement and time to service
disengagement, assessed by consulting case records
and local databases;
 change from baseline to 9 month follow-up in
patient needs for care, assessed using the CAN
 change from baseline to 9 month follow-up in
expressed emotions of the key relative, measured
using the LEE change from baseline to 9 month follow-up in
burden of the key relative, measured using the IEQ
 service satisfaction in patients and relatives,
measured using the VSSS-EU and VSSS-Relatives
scales.
Reporting and quantification of side-effects
No specific side-effects are expected from the interven-
tions being tested. Monitoring and registration of death
(from any cause), suicide attempts, serious medication
side-effects (neuroleptic malignant syndrome, tardive
dyskinesia, akathisia, and tremors) for participants in
both treatment arms will be maintained over the study
duration. Across both arms, these adverse events will be
recorded by the treating psychiatrists as they occur and
by the assessors who collect data at 9 months.
Sample size and power calculations
For power calculations, we consider rates of relapses
and/or severe psychotic symptoms to be the primary
outcome measures. For a conventional trial with
randomization of individual patients [51], a total of ap-
proximately 250 patients will detect a difference in terms
of rates at 9 months from 25% in the TAU arm to 10%
in the experimental treatment arm, with a power of 80%
(two-sided test at 5%, http://statpages.org/proppowr.
html). This difference could represent a plausible and
realistic intervention effect [7,52,53]. The cluster
randomization used for the GET UP PIANO trial pur-
poses might result in reduced efficiency and loss of
power because the within-cluster responses tend to be
more similar than those of individuals from different
clusters (commonalities in selection, exposure, shared
environment, mutual interaction). A larger sample size
will therefore be needed to compensate for this
clustering effect. The clustering effect is measured as
1 + (m−1)ρ, where m is the number of participants per
cluster (assuming equal sizes for clusters) and ρ the
intra-cluster correlation coefficient (ICC). This cluster-
ing effect is used as an inflation factor to increase the
sample size calculated, as required by an individual
randomization trial [51,54]. Our approach is simplified
because it does not take into account variations in the
number of participants in each cluster and assumes m to
be the average number of participants per cluster. Al-
though this type of imbalance in cluster size may reduce
the power of the trial, the loss is negligible for studies
with more than 100 patients per arm [55]. Based on the
additional assumptions of an ICC of 0.05 and an average
of four eligible and consenting patients in each cluster,
the number of patients required would be approximately
350. With a loss to follow-up of approximately 10%, we
expect that a sample size of about 400 patients will yield
sufficient power. Assuming an expected incidence rate
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year [56] and a rate for affective psychoses rate of 6 per
100,000 per year [57], a reasonable estimate of the num-
ber of patients expected over 1 year from the 116 par-
ticipating CMCHs (total population 9,203,093; at-risk
population about 50%) is about 800. Assuming an attri-
tion rate of approximately 50%, due to a number of rea-
sons, both at the cluster level (drop-out of CMHCs from
the study, lack of cooperation) and at the individual level
(participants who do not seek help, do not attend the
public services, refuse to be involved in the study), the
number of patients available for the trial would be about
400.
With regard to family members, the key-relative burden
assessed by using the IEQ was used as the outcome meas-
ure for power calculation. From previous studies [58,59],
we expect the mean reduction of total IEQ score to be 8.0
in a total score range of 27 to 135 for the family members
allocated to TAU, with a standard deviation of 15.0. We
want to be able to detect at least a 50% greater reduction in
the burden in the experimental intervention group at the
0.05 level of significance and with a power of 80%. For a
conventional trial with randomization of individual sub-
jects, a sample size of 280 will allow detection of this differ-
ence in key-relative burden. By applying the inflation factor
to account for the cluster design, the sample size required
would increase up to 320. Based on the expected number
of patients (n=400), it seems reasonable to assume that a
20% of family members will not be traceable, will refuse to
participate, or will drop out from the trial. Thus, the
expected number of about 300 family members would be
sufficient to detect a significant difference in burden.
Blinding
In this pragmatic trial, implemented in the CMHC set-
tings that are the randomization units of the trial, the
blinding of patients, clinicians, and raters working on
site is not possible. However, every effort will be made
to preserve the independence of the raters. They are not
involved in the treatment sessions, and any conflict of
interest is accurately prevented and monitored. In any
case, possible bias associated with lack of blinding is
expected to have limited effect on the estimates of inter-
vention effects because the primary outcomes (relapses
and/or changes in psychopathology) are objective clinical
assessments [60,61]. Moreover, for the assessment of pri-
mary outcomes, raw data will be analyzed whenever pos-
sible by paired and independent members of the
research team who are blinded to the randomization
arm.
Types of analysis
All study data are entered into an electronic database
and stored at the World Health OrganizationCollaborative Center for Research and Training in Men-
tal Health and Service Evaluation of the University of
Verona. The trial data manager is not involved in deter-
mining patient eligibility, administering treatment, or de-
termining outcomes. A set of electronic and manual edit
checks ensures data correctness and consistency. In ac-
cordance with the Declaration of Helsinki, patient confi-
dentiality is fully preserved during all the study phases
via anonymous data recording. Patients are assigned an
identification number, both in the baseline and follow-
up forms, and in the database. Anonymized data will be
transferred to the trial statistician for the analyses.
Data will be analyzed when information is available for
all participants. The pattern of missing values will be
explored, and interactions between treatment group and
completers/non-completers will be examined.
Statistical analysis will be based on an intention-to-
treat (ITT) basis, comparing outcomes from all patients
within CMHCs allocated to experimental treatment with
those allocated to TAU. The emphasis will be on differ-
ences between these groups in terms of changes from
the pre-intervention to the post-intervention phases, by
taking appropriate account of the clustering. The ITT
principle will allow for potential biases arising from loss
to follow-up, under the assumption that missing out-
comes were missing at random (MAR) using the termin-
ology of Little and Rubin [62].
Owing to the characteristics of the cluster
randomization study design, the statistical analysis can-
not be masked, that is, the trial statistician will not be
blinded to the treatment groups, although he/she will
not be involved in determining patient eligibility, in
administering treatment, in measuring outcomes, or in
entering data. All analyses will be performed using Stata
software (11.0 for Windows; Stata Corp.).
Statistical analysis
Findings will be reported in accordance with the CON-
SORT guidelines for cluster randomized trials [63,64].
The nesting of different units of observation (patients)
in each unit of assignment (CMHCs) and in different
units of experimental condition assignment (experimen-
tal treatment versus TAU) will create the hierarchical
structure that is characteristic of cluster randomized
trials. Patients will be the first level, CMHCs the second
level, and treatment assignment the third level of
aggregation.
Firstly, the baseline characteristics of patients and clusters
will be compared to ensure effective randomization. To
compare differences in outcomes between experimental
treatment and TAU, we will use an analysis appropriate for
cluster randomized trials [65], namely, a t-test weighted by
an inverse binomial variance weight for binary outcomes,
and a t-test weighted by an inverse variance for continuous
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chosen condition-level summary statistic (for example,
mean or proportion) against the variation of the corre-
sponding group-level statistic through the use of weights
proportional to the inverse of the variances of the cluster
means or proportions. Regarding multilevel analyses, Mur-
ray et al. [13] reviewed model-based methods appropriate
for the cluster randomized design. Random-effects regres-
sion models [67] will be used to compare treatment out-
comes between the study groups because they include all
sources of random variation, and reflect regression adjust-
ment for covariates at both individual and cluster level. The
‘gllamm’ command in Stata 11.0 will be used for this pur-
pose. The effects of baseline covariates expected to have an
important influence on the primary outcome variables will
be controlled for, by comparing covariate-adjusted analyses
with unadjusted analyses. Specifically, important covariates
for the outcome are gender, duration of untreated psych-
osis, and age of onset. The presence of multicolinearity,
interaction, and higher power terms will be assessed to
check final model validity. Mixed models will allow for the
inclusion of data from patients with incomplete observa-
tions at follow-up. We will allow for the presence of miss-
ing outcome data under the assumption that the data are
missing completely at random, conditional on the covari-
ates included in the models (that is, MAR, using the ter-
minology of Little and Rubin [62]). Statistical significance
will be defined at two-sided p< 0.05. All analyses will be
performed using Stata software (version 11.0 for Windows;
Stata Corp).Planned subgroup analyses
The primary outcome may vary in subgroups of patients
with different baseline characteristics. Consequently, sec-
ondary analyses will be carried out to compare the out-
come in groups of patients with specific characteristics
identified a priori (such as gender, age of onset, duration
of untreated psychosis), so as not to pose multiplicity
concerns. Power for these subgroup analyses has not
been specifically allowed for, and so they will be treated
as exploratory, and will not affect the trial’s conclusions.
Planned subgroup analysis will be performed by using
the ITT approach, based on subgroups [68].Informed consent form and information sheet
Eligible participants are asked to participate only after
receiving a detailed explanation of the nature, scope,
and possible consequences of the trial. Participants re-
ceive an informed consent document including both
information about the study and the consent form to
sign. This document contains all the elements required
by the Guidelines of Good Clinical Practice and any
additional elements required by local regulations. Thedocument is in a language understandable to the parti-
cipants and specifies the person (either a psychiatrist
or a psychologist) who informs the participant. After
reading the informed consent document, the patient or
their legal representative gives consent in writing. The
patient’s consent is confirmed at the time of the con-
sent by the personally dated signature of the partici-
pant and by the personally dated signature of the
person conducting the informed consent discussion. In
accordance with the Guideline of Good Clinical Prac-
tice, participants enrolled in the trial with the consent
of the participants’ legally acceptable representative
are informed about the trial to the extent compatible
with the participants’ understanding and, if capable,
the participant is asked to sign and personally date the
written informed consent.
Participating patients are asked to give consent for the
involvement of their family members in the study, and
those providing consent receive an informed consent
document that includes both information about the
study and the consent form, which is given to family
members. The staff member or the researcher informing
family members is a psychiatrist or a psychologist. After
reading the informed consent document, the participant
gives consent in writing.
Independent data-monitoring committee
The trial is regulated by an independent trial monitoring
committee including experts who hae reviewed and
approved the protocol before commencing enrolment. Ad-
verse events will be monitored and discussed with this
committee.Trial status
The trial began on 1 April 2010 and is still ongoing. The
patient enrolment will finish on 31 January 2012, and the
follow-up assessments are expected to be completed on 31
May 2012.Discussion
Psychotic disorders are the most severely disabling of all
mental illnesses, leading to great personal suffering for
patients and their family members, due to still-persisting
social stigma and repeated post-relapse hospitalizations.
Most clinical and psychosocial deterioration in schizo-
phrenia has been found to occur within the first 5 years
of illness onset, suggesting this phase as a “critical
period” for initiating treatment. Thus, the most recent
research applications in the field have begun to focus on
the aspects of early detection and intervention, with
findings now revealing a direct relation between quality
of clinical/social response and swiftness of treatment
after psychosis onset. International treatment guidelines
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and integrated pharmacological and psychosocial ap-
proach, including cognitive behavioural psychotherapy
for patients and psycho-educational intervention for
their family members. Hence, policy planning must also
be based on a combination of these different compo-
nents in a multi-element perspective. However, there is
little knowledge on how these procedures can be best
integrated into current CMHC clinical practices. The
challenge is therefore that of learning how to effectively
manage many inter-dependent organisational problems
and to concurrently develop and implement intervention
programmes that are targeted, effective, and tailored to
patients and their family members. Moreover, all of this
must be achieved in a context of great (patient, family,
clinical, and social-relational) variability.
The Research Programme “Genetics Endophenotypes
and Treatment: Understanding early Psychosis” (GET-
UP) aims to apply innovative and targeted forms of early
psychosis onset intervention and to test its effectiveness
and feasibility in Italian Community Mental Health Cen-
tres. The randomised controlled trial launched in the
frame of the GET UP Research Programme, whose
protocol is described in this paper, is based on sophisti-
cated epidemiological, clinical, biological, and neurocog-
nitive investigations and involves 117 Mental Health
Centres located throughout a 10 million-inhabitant
catchment area, including two Regions (Veneto and
Emilia Romagna) and the Bolzano, Florence, and Milan
provinces. Workers in these catchment areas are trained
in the above-mentioned forms of intervention. This ini-
tiative is expected to produce scientific knowledge useful
to activate a virtuous circle to foster the dissemination
of early prevention and intervention practices–not only
for psychoses, but also in other mental health spheres.Abbreviations
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GET UP - Genetics, Endophenotypes, Treatment: Understanding Early
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National Coordinator: Professor Mirella Ruggeri (Verona)
Leading Project: PIANO (Psychosis: Early Intervention and Assessment of
Needs and Outcome)
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Mario Ballarin
Project: TRUMPET (TRaining and Understanding of Service Models for Psych-
osis Early Treatment)
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Project: GUITAR (Genetic data Utilization and Implementation of Targeted
Drug Administration in the Clinical Routine)
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Leading administrative institution: IRCCS Centro S.Giovanni di Dio Fatebene-
fratelli, Brescia
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Zanardini
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Enrollment and treatment research units
Research unit Western Veneto
Coordinator: Antonio Lasalvia (Verona)
Leading administrative institution: Azienda Ospedaliera Universitaria Integrata,
Verona.
Coordinating center: Mariaelena Bertani, Sarah Bissoli, Lorenza Lazzarotto.
Participating MHCs: TAU Arm: Ulss 3 (Bassano), Ulss 4 Alto Vicentino (Thiene),
Ulss 5 Montecchio (CSM ‘Centro/Sud’), Ulss 6 Vicenza (Secondo CSM), Ulss 18
Rovigo (Rovigo), Ulss 20 Verona (II° Servizio), Ulss 22 Bussolengo (Isola della
Scala). Experimental Arm: Ulss 5 Montecchio (Nord), Ulss 6 Vicenza (Primo
CSM; CSM Noventa), Ulss 18 Rovigo (Badia), Ulss 19 Adria (Adria), Ulss 20 Ver-
ona (I° Servizio; III° Servizio; IV° Servizio CSM ‘La Filanda’),Ulss 21 Legnago
(CSM ‘Il Tulipano’; CSM ‘il Girasole’).
MHC reference contacts: Sonia Bardella, Francesco Gardellin, Dario Lamonaca,
Antonio Lasalvia, Marco Lunardon, Renato Magnabosco, Marilena Martucci,
Stylianos Nicolau, Francesco Nifosì, Michele Pavanati, Massimo Rossi, Carlo Pi-
azza, Gabriella Piccione, Alessandra Sala, Annalisa Sale, Benedetta Stefani,
Spyridon Zotos.
CBT staff: Mirko Balbo, Ileana Boggian, Enrico Ceccato, Rosa Dall’Agnola, Fran-
cesco Gardellin, Barbara Girotto, Claudia Goss, Dario Lamonaca, Antonio
Lasalvia, Roberta Leoni, Alessia Mai, Annalisa Pasqualini, Michele Pavanati,
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Stefania Strizzolo, Spyridon Zotos, Anna Urbani.
Family intervention staff: Flavia Aldi, Barbara Bianchi, Paola Cappellari, Raf-
faello Conti, Laura De Battisti, Ermanna Lazzarin, Silvia Merlin, Giuseppe
Migliorini, Tecla Pozzan, Lucio Sarto, Stefania Visonà.
Case management staff: Andrea Brazzoli, Antonella Campi, Roberta Carmag-
nani, Sabrina Giambelli, Annalisa Gianella, Lino Lunardi, Davide Madaghiele,
Paola Maestrelli, Lidia Paiola, Elisa Posteri, Loretta Viola, Valentina Zamberlan,
Marta Zenari.
Staff for biological sample processing and support for brain imaging proce-
dures: Sarah Tosato, Martina Zanoni, Giovanni Bonadonna, Mariacristina
Bonomo.
Research unit Eastern Veneto
Coordinator: Paolo Santonastaso (Padova)
Leading administrative institution: University of Padova.
Coordinating center: Carla Cremonese, Paolo Scocco, Angela Veronese.
Participating MHCs: TAU Arm: Ulss 8 (Castelfranco), Ulss 9 (Treviso Nord;
Oderzo), Ulss 10 (San Donà di Piave), Ulss 12 (Venezia; Mestre sud), Ulss 13
(Dolo), Ulss 14 (Piove di Sacco), Ulss 15 (Cittadella), Ulss 16 (II° Servizio), Ulss
17 (Este; Montagnana). Experimental Arm: Ulss 8 (Montebelluna; Valdobbia-
dene), Ulss 9 (Treviso; Mogliano Veneto), Ulss 10 (PortogReserach Unitaro),
Ulss 12 (Mestre Centro), Ulss 13 (Mirano), Ulss 14 (Chioggia I°; Cavarzere), Ulss
15 (Camposanpiero), Ulss 16 (I° Srvizio; III° Servizio), Ulss 17 (Monselice;
Conselve).
MHC reference contacts: Patrizia Anderle, Andrea Angelozzi, Isabelle Amalric
Gabriella Baron,, Enrico Bruttomesso Fabio Candeago, Franco Castelli, Maria
Chieco, Carla Cremonese, Enrico Di Costanzo, Mario Derossi, Michele Dori-
guzzi, Osvaldo Galvano, Marcello Lattanzi, Roberto Lezzi, Marisa Marcato,
Alessandro Marcolin, Franco Marini,, Manlio Matranga, Donato Scalabrin,
Maria Zucchetto, Flavio Zadro.
CBT staff: Giovanni Austoni, Maria Bianco, Francesca Bordino, Filippo Dario,
Alessandro De Risio, Aldo Gatto, Simona Granà, Emanuele Favero, Anna Fran-
ceschini, Silvia Friederici, Vanna Marangon, Michela Pascolo, Luana Ramon,,
Paolo Scocco, Angela Veronese, Stefania Zambolin, Rossana Riolo
Family intervention staff: Antonella Buffon, Carla Cremonese, Elena Di Bortolo,
Silvia Friederici, Stefania Fortin, Marisa Marcato, Francesco Matarrese, Simona
Mogni, Novella Codemo, Alessio Russi, Alessandra Silvestro, Elena Turella,
Paola Viel, Anna Dominoni
Case management staff: Lorenzo Andreose, Mario Boemio, Loretta Bressan,
Arianna Cabbia, Elisabetta Canesso, Romina Cian, Claudia Dal Piccol, Maria
Manuela Dalla Pasqua, Anna Di Prisco, Lorena Mantellato, Monica Luison,
Sandra Morgante, Mirna Santi, Moreno Sacillotto, Mauro Scabbio, Patrizia
Sponga, MLuisa Sguotto, Flavia Stach, MGrazia Vettorato, Giorgio Martinello,
Francesca Dassiè, Stefano Marino, Linda Cibiniel, Ilenia Masetto, Marisa
Marcato
Staff for biological sample processing and support for brain imaging proce-
dures: Oscar Cabianca, Amalia Valente, Livio Caberlotto, Alberto Passoni, Patri-
zia Flumian, Luigino Daniel, Massimo Gion, Saverio Stanziale, Flora Alborino,
Vladimiro Bortolozzo, Lucio Bacelle, Leonarda Bicciato, Daniela Basso, Filippo
Navaglia, Fabio Manoni, Mauro Ercolin.
Research unit Emilia
Coordinators: Giovanni Neri (Modena), Franco Giubilini (Parma)
Leading administrative institution: Azienda ULSS, Parma
Coordinating center: Massimiliano Imbesi, Emanuela Leuci, Fausto Mazzi,
Enrico Semrov.
Participating MHCs: TAU Arm: Piacenza (Castel S.Giovanni), Parma (Parma Est;
Sud Est; Valli Taro e Ceno), Reggio Emilia (CastelNovo nei Monti; Montecchio),
Modena (Mirandola; Polo Ovest; Sassuolo; Pavullo). Experimental Arm: Pia-
cenza (Piacenza; Fiorenzuola), Parma (Nord; Ovest; Fidenza), Reggio Emilia
(Correggio; Guastalla; Reggio Emilia III; Reggio Emilia; Scandiano), Modena
(Carpi; Polo Est; Vignola).
MHC reference contacts: Silvio Anelli, Mario Amore, Laura Bigi, Welsch Britta,
Giovanna Barazzoni Anna, Uobes Bonatti, Maria Borziani, Stefano Crosato, Isa-
bella Fabris, Raffaele Galluccio, Margherita Galeotti, Mauro Gozzi, Vanna
Greco, Emanuele Guagnini, Stefania Pagani, Silvio Maccherozzi, Raffaello Mal-
vasi, Francesco Marchi, Ermanno Melato, Elena Mazzucchi, Franco Marzullo,
Pietro Pellegrini, Nicoletta Petrolini, Paolo Volta.
CBT staff: Silvio Anelli, Franca Bonara, Elisabetta Brusamonti, Roberto Croci,
Ivana Flamia, Francesca Fontana, Romina Losi, Fausto Mazzi, Roberto March-
ioro, Stefania Pagani, Luigi Raffaini,, Luca Ruju, Antonio Saginario, MGrazia
Tondelli, Donatella Marrama.Family intervention staff: Lucia Bernardelli, Federica Bonacini, Annaluisa Flor-
indo, Marina Merli, Patrizia Nappo, Lorena Sola, Ornella Tondelli, Matteo
Tonna, MTeresa Torre, Morena Tosatti, Gloria Venturelli, Daria Zampolla.
Case management staff: Antonia Bernardi, Cinzia Cavalli, Lorena Cigala, Cinzia
Ciraudo, Antonia Di Bari, Lorena Ferri, Fabiana Gombi, Sonia Leurini, Elena
Mandatelli, Stefano Maccaferri, Mara Oroboncoide, Barbara Pisa, Cristina Ricci.
Staff for biological sample processing and support for brain imaging proce-
dures: Enrica Poggi, Mara Oroboncoide, Corrado Zurlini, Monica Malpeli, Ros-
sana Colla, Elvira Teodori, Luigi Vecchia, Rocco D'Andrea, Tommaso Trenti,
Paola Paolini, Fausto Mazzi, Paolo Carpeggiani
Research unit Romagna:
Coordinators: Francesca Pileggi (Bologna), Daniela Ghigi (Rimini)
Leading administrative institution: Azienda ULSS, Rimini
Coordinating center: Mariateresa Gagliostro, Michela Pratelli, Paola Rucci
Participating MHCs: TAU Arm: Bologna (Zanolini; Scalo; Casalecchio; Vergato;
San Giovanni), Ferrara (CSA Ferrara; SIPI Ferrara Sud; Codigoro; Portomag-
giore), Ravenna (Ravenna; Fenza), Forlì (Forlì), Cesena (Cesena), Rimini (Ric-
cione). Experimental Arm: Bologna (Mazzacorati; Tiarini, Nani; S. Lazzaro;
Budrio; San Giorgio), Imola (UOT_Imola), Ferarra (Copparo; Ferrara Nord;
Cento), Ravenna (Lugo), Cesena (Rubicone), Rimini (Rimini).
MHC reference contacts: Antonio Antonelli, Luana Battistini, Francesca Bellini,
Eva Bonini, Caterina Bruschi Rossella Capelli,, Cinzia DiDomizio, Chiara Drei,
Giuseppe Fucci, Alessandra Gualandi, Maria Rosaria Grazia, AnnaM. Losi, Fed-
erica Mazzanti Paola Mazzoni, Daniela Marangoni, Giuseppe Monna, Marco
Morselli, Alessandro Oggioni, Silvio Oprandi, Walter Paganelli, Morena Passer-
ini, Maria Piscitelli, Gregorio Reggiani, Gabriella Rossi, Federica Salvatori,
Simona Trasforini,, Carlo Uslenghi, Simona Veggetti
CBT staff: Giovanna Bartolucci, Rosita Baruffa, Francesca Bellini, Raffaella Ber-
telli, Lidia Borghi, Patrizia Ciavarella, Cinzia DiDomizio, Giuseppe Monna, Ales-
sandro Oggioni, Elisabetta Paltrinieri, Francesco Rizzardi, Piera Serra, Damiano
Suzzi, Uslenghi Carlo, Maria Piscitelli
Family intervention staff: Paolo Arienti, Fabio Aureli, Rosita Avanzi, Vincenzo
Callegari, Alessandra Corsino, Paolo Host, Rossella Michetti, Michela Pratelli,
Francesco Rizzo, Paola Simoncelli, Elena Soldati, Eraldo Succi.
Case management staff: Massimo Bertozzi, Elisa Canetti, Luca Cavicchioli, Elisa
Ceccarelli, Stefano Cenni, Glenda Marzola, Vanessa Gallina, Carla Leoni, An-
drea Olivieri, Elena Piccolo, Sabrina Ravagli, Rosaria Russo, Daniele Tedeschini.
Staff for biological sample processing and support for brain imaging proce-
dures: Marina Verenini, Walter Abram, Veronica Granata, Alessandro Curcio,
Giovanni Guerra, Samuela Granini, Lara Natali, Enrica Montanari, Fulvia Pasi,
Umbertina Ventura, Stefania Valenti, Masi Francesca, Rossano Farneti, Paolo
Ravagli, Romina Floris, Otello Maroncelli, Gianbattista Volpones, Donatella
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